MedTrace Logo

Audit and Screening Study to Determine the Prevalence of Peripheral Arterial Disease

NCT00928629 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1000

Last updated 2009-11-13

No results posted yet for this study

Summary

The primary objective of the study is to establish the prevalence of lower extremity peripheral arterial disease (PAD), defined as an ankle-brachial index of less than or equal to 0.9, in subjects with at least two of the specified cardiovascular disease (CVD) risk factors, with no overt cardiovascular disease.

Conditions

  • Peripheral Arterial Disease

Interventions

PROCEDURE

Ankle-brachial index (ABI) Screening Test

Patients will undergo an ABI measurement

Sponsors & Collaborators

  • Pretium Pty Ltd

    collaborator UNKNOWN

  • AstraZeneca

    lead INDUSTRY

Principal Investigators

  • Simon Fisher · AstraZeneca

  • Amelia Siu · AstraZeneca

  • David Sullivan · Central Clinical School, The University of Sydney, Sydney, Australia

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Completion
2009-10-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00928629 on ClinicalTrials.gov